Impact of Daily Image Guided Patient Setup on Bone Marrow Sparing in Cervical Cancer Patients Undergoing IMRT

2008 ◽  
Vol 72 (1) ◽  
pp. S582-S583 ◽  
Author(s):  
J.H. Lewis ◽  
N. Tyagi ◽  
C.M. Yashar ◽  
D. Vo ◽  
L.K. Mell ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Image Guided ◽  
Patient Setup ◽  
Bone Marrow Sparing

Phase III randomized trial of image-guided bone marrow-sparing intensity modulated radiation therapy (IG-BMS-IMRT) for locoregionally advanced cervical cancer: The INTERTECC-3 trial.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. TPS5600-TPS5600
Author(s):  
Loren K. Mell ◽  
Igor Sirak ◽  
Lorraine Portelance ◽  
Aaron Howard Wolfson ◽  
Alexandra J. Stewart ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cervical Cancer ◽  
Bone Marrow ◽  
Intensity Modulated Radiation Therapy ◽  
Phase Iii ◽  
Image Guided ◽  
Intensity Modulated ◽  
Stage Ib ◽  
Bone Marrow Sparing ◽  
The U.S

TPS5600 Background: Cervical cancer is a leading cause of cancer death in women worldwide. Image-guided bone marrow-sparing intensity modulated radiation therapy (IG-BMS-IMRT) has shown potential to reduce acute toxicity of chemoradiotherapy and improve chemotherapy delivery in phase I and II trials (Mell LK, Sirák I, Wei L, et al. Bone Marrow-sparing IMRT With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2). Int J Radiat Oncol Biol Phys 2017;97:536-545. Mell LK, Saenz CC, Yashar CM, et al. Phase I Trial of Bone Marrow Sparing IMRT With Concurrent Cisplatin and Gemcitabine in Stage IB-IVA Cervical Cancer (abstr.) Int J Radiat Oncol Biol Phys 2016; 96: S14.). Methods: INTERTECC-3 is a randomized phase III trial designed to test the effect of IG-BMS-IMRT on progression-free survival (PFS) for women with unresected FIGO stage IB-IVA cervical carcinoma (clinicaltrials.gov #NCT01554397). It presently involves centers in the U.S., Czech Republic, U.K., India, Japan, and China. Women are randomized 3:2 to either (A) IG-BMS-IMRT or (B) standard chemoradiation, with 6 cycles of concurrent cisplatin (40 mg/m2) weekly in both arms. Secondary objectives are to compare overall survival, treatment-related toxicity, disease recurrence, quality of life, chemotherapy delivery, and radiation quality assurance. Planning objectives require maintaining pelvic marrow and active marrow mean doses < 27 Gy and < 28.5 Gy respectively. Correlative studies involve longitudinal collection of magnetic resonance restriction spectrum imaging and 18F-fluorothydimine positron emission tomography scans to assess imaging biomarkers of treatment response in select patients. 415 women will be enrolled to determine if IG-BMS-IMRT improves the median PFS from 3.2 to 5.0 years with 80% power and alpha = 0.05. INTERTECC-3 opened in the U.S. and Czech Republic in 2016. To date, 17 patients have been randomized. The trial will be activated at additional international sites in late 2017 and 2018. We are seeking to recruit sites who wish to collaborate. Clinical trial information: NCT01554397.

scholarly journals Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties

2015 ◽  
Vol 115 (3) ◽  
pp. 373-378 ◽  
Author(s):  
Eric Dinges ◽  
Nicole Felderman ◽  
Sarah McGuire ◽  
Brandie Gross ◽  
Sudershan Bhatia ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Bone Marrow ◽  
Proton Therapy ◽  
Intensity Modulated Proton Therapy ◽  
Intensity Modulated ◽  
Bone Marrow Sparing

SU-E-T-453: PET Image-Guided Dose Escalation Study for Cervical Cancer Patients Receiving HDR Brachytherapy

2013 ◽  
Vol 40 (6Part17) ◽  
pp. 309-309
Author(s):  
J Anderson ◽  
K Kiel ◽  
R Yao ◽  
Y Liao ◽  
D Bernard ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Patients ◽  
Dose Escalation ◽  
Hdr Brachytherapy ◽  
Dose Escalation Study ◽  
Image Guided
Sign in / Sign up

Export Citation Format

Share Document